A panel of investors and leaders in healtech expects investment in health tech to decline, but still foresees opportunities for companies working on solutions that will transform overall health care such as AI, ML, mental health and health equity.

In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.

Pear Therapeutics is restructuring itself to lower costs following repeated disappointing performances.

Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.